(Q37316174)

19 August 2017

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program (English)

1 reference

19 August 2017

1

Richard Gorlick

1 reference

19 August 2017

3

Peter J Houghton

1 reference

19 August 2017

12

John M Maris

1 reference

19 August 2017

14

Malcolm A Smith

1 reference

19 August 2017

9

Richard Lock

1 reference

19 August 2017

2

E Anders Kolb

1 reference

19 August 2017

8

Stephen T Keir

1 reference

19 August 2017

10

Hernan Carol

1 reference

19 August 2017

7

Clinton Stewart

1 reference

19 August 2017

11

C Patrick Reynolds

1 reference

19 August 2017

Christopher L Morton

4

1 reference

19 August 2017

Doris Phelps

series ordinal

5

1 reference

19 August 2017

Paula Schaiquevich

series ordinal

6

1 reference

19 August 2017

Jianrong Wu

series ordinal

13

1 reference

19 August 2017

language of work or name

1 reference

1 October 2009

1 reference

19 August 2017

Pediatric Blood & Cancer

1 reference

19 August 2017

53

1 reference

19 August 2017

4

1 reference

19 August 2017

594-598

1 reference

Epidermal growth factor receptor inhibitors in non-small cell lung cancer

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

ERBB2 in pediatric cancer: innocent until proven guilty

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

The protein tyrosine kinase family of the human genome

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

The pediatric preclinical testing program: description of models and early testing results.

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731000

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19554571

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

ErbB2 expression is correlated with increased survival of patients with osteosarcoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19554571

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PBC.21989

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19554571

1 reference